On November 3, 2025 Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, reported two poster presentations, including initial data from the RALLY-MF Phase 2 trial of DISC-0974 in anemia of MF, at the upcoming American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, which will be held in Orlando, FL on December 6-9, 2025.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The highlight of our ASH (Free ASH Whitepaper) presentations this year will be an initial look at data from RALLY-MF, our Phase 2 trial of DISC-0974 in anemia of myelofibrosis," said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc Medicine. "Following the strong Phase 1b results we presented at ASH (Free ASH Whitepaper) last year, we are eager to share an update on this program, including results from more patients from across the range of MF anemia patients, as a monotherapy and in combination with JAK inhibitor backbone therapies, including ruxolitinib and momelotinib. We will also present a poster on the design of our ongoing Phase 2 trial of DISC-3405 in polycythemia vera. We expect to share an initial readout for this trial, as well as for the Phase 1b trial of DISC-3405 in sickle cell disease, in 2026."
Management will host a call during the ASH (Free ASH Whitepaper) meeting to review highlights of the presented data and plans for next steps in development on Sunday, December 7 at 7:30am EST. Please register for the event on the Events and Presentations page of Disc’s website (View Source).
Details of Poster Presentations:
The abstracts are now available through the ASH (Free ASH Whitepaper) conference website. Pursuant to Disc Medicine practice, the clinical study abstracts published today contain previously presented data; new data and analyses are reserved for presentation at the conference.
DISC-0974 Poster Presentation:
Publication Number: 2042
Title: RALLY MF: A phase 2 Study of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia
Date / Time: Saturday, December 6, 5:30 pm – 7:30pm EST
Presenting Author: Naseema Gangat, M.B.B.S.
DISC-3405 Poster Presentation:
Publication Number: 2053
Title: A phase 2, open-label study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of DISC-3405 in participants with polycythemia vera (PV)
Date / Time: Saturday, December 6, 5:30 pm – 7:30pm EST
Presenting Author: Marcus Carden, M.D., M.Sc.
(Press release, Disc Medicine, NOV 3, 2025, View Sourcenews-releases/news-release-details/disc-medicine-announces-presentation-initial-data-rally-mf-phase [SID1234659286])